BRAF and neoplasm: BRAF mutations, either V600E or V600K, identified by standard clinical testing using paraffin-embedded patient tumour tissue (Supplementary Table 2), was confirmed in the fresh patient tumour and the corresponding first generation PDX (Fig. 1a; Supplementary Table 3), and identified in all subsequent generations of PDXs (Fig. 1b; Supplementary Table 3).